Apnimed will be waiting for the readout from a second Phase III trial before it ...
In April 2025, the European Medicines Agency (EMA) approved Eisai and Biogen’s L...
The US FDA has approved Incyte’s Zynyz (retifanlimab-dlwr) in conjunction with c...
Pfizer has signed a worldwide licensing agreement, excluding China, with biophar...
Tezepelumab demonstrated clinically relevant benefits in specific inflammatory s...
At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nu...
At a recent gathering, experts in the Swiss biotech and pharma sector underscore...
The sale brings attention back to privacy concerns as Regeneron now controls gen...
Leuven, 20 May 2025 – Breakthrough research from the laboratory led by Professor...
In a groundbreaking advancement that could redefine trauma care in prehospital s...
In the rapidly evolving landscape of pediatric pharmacotherapy, ensuring the pre...
In a groundbreaking synthesis of genetic research published in Genomic Psychiatr...
In a groundbreaking study published in Nature Communications, researchers have u...
A startling new study from the NYU Grossman School of Medicine reveals a dramati...
As the global population ages, the challenge of effectively treating cancer in o...
